Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

ACE2 Antikörper

Dieses Maus Monoklonal-Antikörper erkennt spezifisch ACE2 in WB, ELISA und FACS. Er zeigt eine Reaktivität gegenüber Human und wurde in 4+ Publikationen erwähnt.
Produktnummer ABIN1169449

Kurzübersicht für ACE2 Antikörper (ABIN1169449)

Target

Alle ACE2 Antikörper anzeigen
ACE2 (Angiotensin I Converting Enzyme 2 (ACE2))

Reaktivität

  • 167
  • 59
  • 55
  • 5
  • 4
  • 3
  • 1
  • 1
  • 1
  • 1
Human

Wirt

  • 148
  • 44
  • 6
  • 1
Maus

Klonalität

  • 127
  • 72
Monoklonal

Konjugat

  • 121
  • 17
  • 12
  • 8
  • 5
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser ACE2 Antikörper ist unkonjugiert

Applikation

  • 157
  • 87
  • 77
  • 49
  • 41
  • 36
  • 30
  • 18
  • 17
  • 14
  • 10
  • 6
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Klon

AC18F
  • Spezifität

    Recognizes human ACE2.

    Kreuzreaktivität

    Human

    Sterilität

    0.2 μm filtered

    Immunogen

    Recombinant human ACE2.

    Isotyp

    IgG1
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konzentration

    Lot specific

    Buffer

    0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.

    Konservierungsmittel

    Without preservative

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Short Term Storage: +4°C
    Long Term Storage: -20°C
    Stable for at least 1 year after receipt when stored at -20°C.

    Haltbarkeit

    12 months
  • Chaouat, Achdout, Kol, Berhani, Roi, Vitner, Melamed, Politi, Zahavy, Brizic, Lenac Rovis, Alfi, Wolf, Jonjic, Israely, Mandelboim: "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection." in: PLoS pathogens, Vol. 17, Issue 12, pp. e1010175, (2022) (PubMed).

    Chaouat, Brizic, Kucan Brlic, Atari, Kliker, Alfi, Mandelboim, Wolf, Tafish, Kol, Jonjic, Mandelboim: "Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern." in: iScience, Vol. 25, Issue 9, pp. 104935, (2022) (PubMed).

    Buchrieser, Dufloo, Hubert, Monel, Planas, Rajah, Planchais, Porrot, Guivel-Benhassine, Van der Werf, Casartelli, Mouquet, Bruel, Schwartz: "Syncytia formation by SARS-CoV-2-infected cells." in: The EMBO journal, pp. e106267, (2020) (PubMed).

    Zulli, Rai, Buxton, Burrell, Hare: "Co-localization of angiotensin-converting enzyme 2-, octomer-4- and CD34-positive cells in rabbit atherosclerotic plaques." in: Experimental physiology, Vol. 93, Issue 5, pp. 564-9, (2008) (PubMed).

  • Target

    ACE2 (Angiotensin I Converting Enzyme 2 (ACE2))

    Andere Bezeichnung

    ACE2

    Hintergrund

    ACE2 has direct effects on cardiac functions. It is expressed predominantly in vascular endothelial cells of the heart and kidney. ACE2 converts angiotensin I to angiotensin 1-9. ACE2 was also identified as a functional receptor for SARS coronavirus.

    UniProt

    Q9BYF1

    Pathways

    ACE Inhibitor Pathway, Peptide Hormone Metabolism, Regulation of Systemic Arterial Blood Pressure by Hormones, Feeding Behaviour
Sie sind hier:
Chat with us!